Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
2022-06-25 · Ionis Pharmaceuticals · original ionis.com ↗
- Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B - Phase 3 clinical study evaluating bepirovirsen as a monotherapy is anticipated to start in the first half of 2023 - GSK to explore potential combination treatments to further reduce the global burden of chronic hepatitis B CARLSBAD, Calif., June 25, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB).
The release as fetched from its publisher. ionis.com ↗